The Estee Lauder Companies takes minority stake in luxury skincare brand
The Estée Lauder Companies has taken a minority stake in luxury clinical skin care brand 111Skin as part of a continued focus on science-driven innovation.
Founded in 2012 by plastic and reconstructive surgeon Yannis Alexandrides, the brand was originally developed to accelerate patients’ healing time following procedures.
Subscribe to TRB111Skin now has a portfolio of more than 30 products anchored by its Black Diamond and Reparative collections. The brand distributes through luxury retail, ecommerce and high end spa channels, including Harrods, Bluemercury, Nordstrom, Mandarin Oriental and Aman. It also has direct-to-consumer business representing around 20% of sales.
Stéphane de La Faverie, president and chief executive of The Estée Lauder Companies. said: “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results.
“111Skin exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy.”evant with today’s consumers.”
In 2025, North America accounted for around 40% of sales but the brand also has an established presence in the UK, China, Europe and Asia Pacific.
Following the investment, Alexandrides will remain actively involved in the brand and will continue to lead 111Skin alongside its management team.
Alexandrides and co-founder Eva Alexandrides said: “We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111Skin.”
